陕西医学杂志2024，Vol.53Issue(7)：958-961,4.DOI:10.3969/j.issn.1000-7377.2024.07.020
含贝达喹啉全口服短程化疗治疗耐多药肺结核疗效及安全性观察临床研究
Efficacy and safety of total oral short-course chemotherapy containing Bedaquinoline in treatment of patients with multidrug resistant pulmonary tuberculosis
摘要
Abstract
Objective:To investigate the efficacy and safety of total oral short-course chemotherapy containing Bedaquinoline in the treatment of multi-drug resistant pulmonary tuberculosis.Methods:A total of 100 patients with MDR-TB were selected and divided into control group(WHO long-course regimen,50 cases)and observation group(including Bedaquinoline short-course regimen,50 cases)by random number table method.The negative conversion rate and cure rate of sputum culture were compared between two group,and the changes of lesions and cavities were observed by chest CT,and the occurrence rate of adverse reactions was recorded.Results:The negative conversion rate at 24 weeks in the observation group was 84.00％(41/50),higher than 74.00％(27/50)in the control group.The improvement of lesion absorption and cavity in the observation group at 36 weeks was better than that in the control group(P＜0.05).The cure rate of observation group was 76.00％(38/50),higher than 52.00％(26/50)of control group(P＜0.05).There were a total of 84 adverse reactions in the control group and 69 adverse reactions in the ob-servation group.There was statistical significance in the occurrence of adverse reactions between the two groups(P＜0.05).Conclusion:Total oral short-course chemotherapy containing Bedaquinoline has short course of treat-ment,high cure and good safety.关键词
耐多药肺结核/贝达喹啉/短程化疗/疗效/不良反应/安全性Key words
Multidrug-resistant tuberculosis/Bedaquinoline/Short-course chemotherapy/Curative effect/Adverse reactions/Security分类
医药卫生引用本文复制引用
李静虹,刘红莲,宗凯仁,周燕红,钟诚..含贝达喹啉全口服短程化疗治疗耐多药肺结核疗效及安全性观察临床研究[J].陕西医学杂志,2024,53(7):958-961,4.基金项目
中央引导地方科技发展基金资助项目(20221ZDG020069) （20221ZDG020069）
江西省应用研究培育计划项目(20212BAG70015) （20212BAG70015）
